Literature DB >> 2939794

Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.

M A Gonzalez, A H Moranchel, S Duran, A Pichardo, J L Magana, B Painter, A Forrest, G L Drusano.   

Abstract

We administered multiple doses of ciprofloxacin intravenously over 30 min every 12 h for 1 week to nine healthy volunteers. Three volunteers received a placebo (vehicle) intravenously. Doses of 100, 150, and 200 mg were evaluated with a 1-week wash-out period intervening between each dose level. Terminal excretion half-lives averaged 3.67 +/- 0.65, 3.60 +/- 0.26, and 4.00 +/- 0.69 h for the 100-, 150-, and 200-mg doses, respectively. Serum clearances were 30.1 +/- 3.4, 29.8 +/- 4.0, and 26.9 +/- 4.1 liters/h per 1.73 m2 for these doses. Urine concentrations remained in excess of the MIC for 90% of the relevant urinary tract pathogens for the full 12-h dosing interval at each dose. Renal clearance accounted for 56 to 71% of the serum clearance. However, because a microbiologic assay was used and biologically active, renally excreted metabolites were identified, the renal clearance determinations are likely to be in excess of the true values. The doses of ciprofloxacin administered intravenously were well tolerated, and the drug concentrations appeared adequate for the treatment of the vast majority of cases of nosocomially acquired sepsis and urinary tract infections. For patients with serious Pseudomonas infections and perhaps staphylococcal infections, either an 8-h dosing schedule or larger doses on a 12-h schedule should be considered.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2939794      PMCID: PMC180225          DOI: 10.1128/AAC.28.2.235

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

2.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

3.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

4.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

5.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine.

Authors:  B Joos; B Ledergerber; M Flepp; J D Bettex; R Lüthy; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

7.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

  7 in total
  21 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men.

Authors:  R E Roddy; H H Handsfield; E W Hook
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

3.  Melting curve analysis for rapid detection of topoisomerase gene mutations in Haemophilus influenzae.

Authors:  Shigeki Nakamura; Katsunori Yanagihara; Yoshitomo Morinaga; Koichi Izumikawa; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Shimeru Kamihira; Shigeru Kohno
Journal:  J Clin Microbiol       Date:  2009-01-07       Impact factor: 5.948

4.  Absolute oral bioavailability of ciprofloxacin.

Authors:  G L Drusano; H C Standiford; K Plaisance; A Forrest; J Leslie; J Caldwell
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

5.  Pharmacokinetics of ciprofloxacin in cystic fibrosis.

Authors:  R L Davis; J R Koup; J Williams-Warren; A Weber; L Heggen; D Stempel; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 6.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

7.  Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa.

Authors:  R A Celesk; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 9.  Quinolones in the elderly.

Authors:  T Bergan
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 10.  Worldwide clinical data on efficacy and safety of ciprofloxacin.

Authors:  P Schacht; G Arcieri; J Branolte; H Bruck; V Chyský; E Griffith; G Gruenwaldt; R Hullmann; C A Konopka; B O'Brien
Journal:  Infection       Date:  1988       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.